圓祥生技logo
Contact LinkedIn
English

Technology

Pipeline

  • Candidate
  • Target/Mechanism
  • Indication
    • Discovery
    Pre-Clinical
    Phase I
    Phase II
    Phase III
  • Partner
IBI302
Inhibit complement activation and angiogenesis
Elderly (wet) macular degeneration (nAMD) patients
Innovent Biologics

Innovent Biologics

(world-wide)

AP505
Avoid T cell inhibition and inhibit angiogenesis
solid tumors
Tasly

Tasly

(China)

AP203
T-cube BsAb
Non-small cell lung cancer, head and neck cancer, and esophageal cancer
AP402
T-cube BsAb
breast cancer
AP601
T-cube BsAb
solid tumors
↑
關閉

建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。

要下載瀏覽器，請直接點擊以下: